Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Change in Inventory (2023 - 2025)

Historic Change in Inventory for Tg Therapeutics (TGTX) over the last 3 years, with Q3 2025 value amounting to -$8.7 million.

  • Tg Therapeutics' Change in Inventory fell 44232.28% to -$8.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $58.8 million, marking a year-over-year increase of 2376.68%. This contributed to the annual value of $66.9 million for FY2024, which is 8098.16% up from last year.
  • Tg Therapeutics' Change in Inventory amounted to -$8.7 million in Q3 2025, which was down 44232.28% from -$3.6 million recorded in Q2 2025.
  • In the past 5 years, Tg Therapeutics' Change in Inventory registered a high of $46.3 million during Q1 2025, and its lowest value of -$8.7 million during Q3 2025.
  • Moreover, its 3-year median value for Change in Inventory was $2.6 million (2024), whereas its average is $12.5 million.
  • In the last 5 years, Tg Therapeutics' Change in Inventory skyrocketed by 35078.1% in 2024 and then tumbled by 44232.28% in 2025.
  • Over the past 3 years, Tg Therapeutics' Change in Inventory (Quarter) stood at $5.5 million in 2023, then skyrocketed by 350.78% to $24.8 million in 2024, then plummeted by 135.03% to -$8.7 million in 2025.
  • Its last three reported values are -$8.7 million in Q3 2025, -$3.6 million for Q2 2025, and $46.3 million during Q1 2025.